Gary Nachman
Stock Analyst at Raymond James
(3.01)
# 751
Out of 5,122 analysts
97
Total ratings
58.9%
Success rate
6.33%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Reiterates: Strong Buy | $85 → $89 | $84.99 | +4.72% | 4 | Oct 30, 2025 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $16.55 | +14.80% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $14.62 | +242.00% | 3 | Oct 20, 2025 | |
| ABBV AbbVie | Reiterates: Outperform | $236 → $250 | $217.11 | +15.15% | 17 | Oct 17, 2025 | |
| AMGN Amgen | Assumes: Market Perform | n/a | $366.20 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.53 | +690.51% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $13.36 | +109.58% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $351.96 | -15.33% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $4.22 | +373.93% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $20.68 | +78.92% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $46.83 | -35.94% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $4.00 | +75.00% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $165.72 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $14.43 | -72.28% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $13.23 | +126.76% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $3.27 | +878.59% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $14.36 | -2.51% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $34.96 | -71.40% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $34.95 | -14.16% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $4.41 | +16,906.80% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $5.66 | +41.34% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $28.61 | -26.60% | 5 | May 11, 2020 |
Ionis Pharmaceuticals
Oct 30, 2025
Reiterates: Strong Buy
Price Target: $85 → $89
Current: $84.99
Upside: +4.72%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $16.55
Upside: +14.80%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $14.62
Upside: +242.00%
AbbVie
Oct 17, 2025
Reiterates: Outperform
Price Target: $236 → $250
Current: $217.11
Upside: +15.15%
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $366.20
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.53
Upside: +690.51%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $13.36
Upside: +109.58%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $351.96
Upside: -15.33%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $4.22
Upside: +373.93%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $20.68
Upside: +78.92%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $46.83
Upside: -35.94%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.00
Upside: +75.00%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $165.72
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $14.43
Upside: -72.28%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $13.23
Upside: +126.76%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.27
Upside: +878.59%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $14.36
Upside: -2.51%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $34.96
Upside: -71.40%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $34.95
Upside: -14.16%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.41
Upside: +16,906.80%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $5.66
Upside: +41.34%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $28.61
Upside: -26.60%